FDA
-
-
-
-
-
-
-
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
-
-
-
-
-
-
-
Three New Studies Show Viz.ai’s Cardio Suite Speeds Detection of Cardiac Disease and Improves Patient Follow-Up
-
-
-
-
-
-
-
Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight
-
-
-
-
-
-
-
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
-
-
-
-
-
-
-
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
-
-
-
-
-
-
-
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
-
-
-
-
-
-
-
Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research
-
327,063 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

